Color Health, the virtual cancer clinic serving employer, health plan, and public sector populations, is now offering the Onclarity HPV Self-Collection Kit through its platform – an FDA-cleared at-home swab-based test that detects 14 high-risk HPV genotypes and individually identifies six specific high-risk strains rather than grouping them into broad categories.
The extended genotyping is what distinguishes this from other HPV tests. Traditional screening clumps high-risk strains into one or two groups, but Onclarity isolates individual genotypes beyond HPV 16, 18, and 45, enabling more precise risk assessment and tailored clinical follow-up. HPV is responsible for over 90% of cervical cancer cases, yet one in four eligible women are not up to date with screening, and 60% of cervical cancers occur in people who haven’t been screened in the last five years or ever.
“Despite cervical cancer being preventable, a woman dies from the disease every 90 seconds,” said Dr. Jeff Andrews, VP of medical sciences at Waters Advanced Diagnostics. “Expanding access to screening is critical, and at-home HPV self-collection removes barriers that keep people from getting screened.”
Color’s clinical model wraps around the test with oncologist-led follow-up through its ASCO-certified Virtual Cancer Clinic. The company reports a 77% increase in screening adherence, 100% clinical follow-up for every abnormal result, and a 66% reduction in time from abnormal result to cancer diagnosis.
